These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 11097051)

  • 1. Linkage of a triple helix-forming oligonucleotide to amsacrine-4-carboxamide derivatives modulates the sequence-selectivity of topoisomerase II-mediated DNA cleavage.
    Arimondo P; Bailly C; Boutorine A; Asseline U; Sun JS; Garestier T; Hélène C
    Nucleosides Nucleotides Nucleic Acids; 2000 Aug; 19(8):1205-18. PubMed ID: 11097051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Position-specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity.
    Bigioni M; Zunino F; Tinelli S; Austin CA; Willmore E; Capranico G
    Biochemistry; 1996 Jan; 35(1):153-9. PubMed ID: 8555169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity.
    Arimondo P; Boukarim C; Bailly C; Dauzonne D; Monneret C
    Anticancer Drug Des; 2000 Dec; 15(6):413-21. PubMed ID: 11716434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple helix-forming oligonucleotides conjugated to new inhibitors of topoisomerase II: synthesis and binding properties.
    Duca M; Oussedik K; Ceccaldi A; Halby L; Guianvarc'h D; Dauzonne D; Monneret C; Sun JS; Arimondo PB
    Bioconjug Chem; 2005; 16(4):873-84. PubMed ID: 16029029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple helix formation inhibits DNA gyrase activity.
    Simon H; Förtsch I; Burckhardt G; Gabrielyan A; Birch-Hirschfeld E; Stelzner A; Prévot-Halter I; Leumann C; Zimmer C
    Antisense Nucleic Acid Drug Dev; 1999 Dec; 9(6):527-31. PubMed ID: 10645778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of cleavage complexes using reactive inhibitor derivatives.
    Kreuzer KN; Freudenreich CH; Pommier Y
    Methods Mol Biol; 2001; 95():89-99. PubMed ID: 11089223
    [No Abstract]   [Full Text] [Related]  

  • 7. Copper-dependent oxidative and topoisomerase II-mediated DNA cleavage by a netropsin/4'-(9-acridinylamino)methanesulfon-m-anisidide combilexin.
    Henichart JP; Waring MJ; Riou JF; Denny WA; Bailly C
    Mol Pharmacol; 1997 Mar; 51(3):448-61. PubMed ID: 9058600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene.
    Pommier Y; Orr A; Kohn KW; Riou JF
    Cancer Res; 1992 Jun; 52(11):3125-30. PubMed ID: 1317259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crystal structure of the topoisomerase II poison 9-amino-[N-(2-dimethylamino)ethyl]acridine-4-carboxamide bound to the DNA hexanucleotide d(CGTACG)2.
    Adams A; Guss JM; Collyer CA; Denny WA; Wakelin LP
    Biochemistry; 1999 Jul; 38(29):9221-33. PubMed ID: 10413496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
    Spitzner JR; Chung IK; Gootz TD; McGuirk PR; Muller MT
    Mol Pharmacol; 1995 Aug; 48(2):238-49. PubMed ID: 7651357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
    Marx G; Zhou H; Graves DE; Osheroff N
    Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-specific sites of topoisomerase II DNA cleavage in Drosophila chromatin: heterogeneous localization and reversibility.
    Borgnetto ME; Zunino F; Tinelli S; Kas E; Capranico G
    Cancer Res; 1996 Apr; 56(8):1855-62. PubMed ID: 8620504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
    Bailly C; Riou JF; Colson P; Houssier C; Rodrigues-Pereira E; Prudhomme M
    Biochemistry; 1997 Apr; 36(13):3917-29. PubMed ID: 9092822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of a DNA-threading netropsin-amsacrine combilexin with DNA and chromatin.
    Bourdouxhe-Housiaux C; Colson P; Houssier C; Waring MJ; Bailly C
    Biochemistry; 1996 Apr; 35(14):4251-64. PubMed ID: 8605173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
    Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
    Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple helix formation by (G,A)-containing oligonucleotides: asymmetric sequence effect.
    Arimondo PB; Barcelo F; Sun JS; Maurizot JC; Garestier T; Hélène C
    Biochemistry; 1998 Nov; 37(47):16627-35. PubMed ID: 9843430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytotoxicity and interaction of amsacrine derivatives with topoisomerase II: role of the 1' substitute on the aniline nucleus].
    René B; Fossé P; Khélifa T; Jacquemin-Sablon A; Bailly C
    Bull Cancer; 1997 Oct; 84(10):941-8. PubMed ID: 9435795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
    Finlay GJ; Atwell GJ; Baguley BC
    Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein.
    Granzen B; Graves DE; Baguley BC; Danks MK; Beck WT
    Oncol Res; 1992; 4(11-12):489-96. PubMed ID: 1363724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
    Zwelling LA; Mitchell MJ; Satitpunwaycha P; Mayes J; Altschuler E; Hinds M; Baguley BC
    Cancer Res; 1992 Jan; 52(1):209-17. PubMed ID: 1309224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.